United States - English - NLM (National Library of Medicine)

bausch health us, llc - amobarbital sodium (unii: g0313knc7d) (amobarbital - unii:gwh6ij239e) - amobarbital sodium 0.5 g in 5 ml - amobarbital sodium is contraindicated in patients who are hypersensitive to barbiturates, in patients with a history of manifest or latent porphyria, and in patients with marked impairment of liver function or respiratory disease in which dyspnea or obstruction is evident. amobarbital sodium is a schedule ii drug. barbiturates may be habit-forming. tolerance, psychological dependence, and physical dependence may occur, especially following prolonged use of high doses of barbiturates. daily administration in excess of 400 mg of pentobarbital or secobarbital for approximately 90 days is likely to produce some degree of physical dependence. a dosage of 600 to 800 mg for at least 35 days is sufficient to produce withdrawal seizures. the average daily dose for the barbiturate addict is usually about 1.5 g. as tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fatal dosage, however, does not increase more than twofold. as this occurs, the margi

Ireland - English - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - amobarbital ephedrine hydrochloride aminophylline -

Ireland - English - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - amobarbital ephedrine hydrochloride aminophylline - capsule

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - pethidine hydrochloride 50 mg/ml; pethidine hydrochloride 50 mg/ml - solution for injection - 50 mg/ml - active: pethidine hydrochloride 50 mg/ml excipient: water for injection active: pethidine hydrochloride 50 mg/ml excipient: sodium hydroxide water for injection - dbl pethidine hydrochloride injection is indicated for administration as an anaesthetic adjunct and for obstetric analgesia. dbl pethidine hydrochloride injection is also indicated for the short-term (24 to 36 hours) management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. it can be given via the following routes of administration – intramuscular (im), subcutaneous (sc), slow intravenous (iv) bolus injection, intravenous infusion and patient-controlled analgesia (pca).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - amobarbital sodium; secobarbital sodium - oral capsule - 50mg ; 50mg

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - aminophylline 130mg; amobarbital 25mg; ephedrine hydrochloride 25mg - capsule - 130mg/25mg/25mg - active: aminophylline 130mg amobarbital 25mg ephedrine hydrochloride 25mg

New Zealand - English - Medsafe (Medicines Safety Authority)

wilson foods limited - aminophylline 25mg; amobarbital 130mg; ephedrine hydrochloride 25mg - capsule - 25mg/130mg/25mg - active: aminophylline 25mg amobarbital 130mg ephedrine hydrochloride 25mg

Canada - English - Health Canada

fresenius kabi canada ltd - vancomycin (vancomycin hydrochloride) - powder for solution - 500mg - vancomycin (vancomycin hydrochloride) 500mg - glycopeptides

Canada - English - Health Canada

fresenius kabi canada ltd - vancomycin (vancomycin hydrochloride) - powder for solution - 1g - vancomycin (vancomycin hydrochloride) 1g - glycopeptides

Canada - English - Health Canada

fresenius kabi canada ltd - vancomycin (vancomycin hydrochloride) - powder for solution - 5g - vancomycin (vancomycin hydrochloride) 5g - glycopeptides